Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

18-06-2021 | ASCO 2021 | Conference coverage | Video

Neoadjuvant talazoparib active in BRCA-mutated early breast cancer

Jennifer Litton discusses results of the NEOTALA trial suggesting patients with germline BRCA1/2-mutant, HER2-negative, early breast cancer may benefit from neoadjuvant treatment with talazoparib (4:56).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript

Related content

05-06-2021 | ASCO 2021 | Conference coverage | News

‘Meaningful benefit’ with adjuvant olaparib in BRCA-mutated early breast cancer

10-06-2021 | ASCO 2021 | Conference coverage | News

Long-term benefits to neoadjuvant durvalumab in triple-negative breast cancer

27-04-2020 | AACR 2020 | News

Neoadjuvant durvalumab, olaparib addition promising in HER2-negative breast cancer

20-09-2020 | ESMO 2020 | Conference coverage | Video

IMpassion031 supports neoadjuvant atezolizumab in early TNBC
Image Credits